Cancer Vaccine Specialist Targovax Appoints Gunnar Gårdemyr As New CEO

NORWAY -- The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO of the company from January 12th, 2015.

Mr Gårdemyr has more than 30 years of international experience in the pharmaceutical and biotech industry, including management, business development, mergers & acquisitions, global marketing and commercial strategy. He currently holds the position of Corporate Advisor for Acino Pharma in Basel, Switzerland. Prior to this he was Senior Vice President, Corporate Development/M&A, Global Business Development, Nycomed and Senior Vice President, Global Marketing, Takeda in Zurich, Switzerland, where he was in charge of the commercial assessment of external business development licensing opportunities.

Mr Gårdemyr started his career in Astra, followed by Ferring, Tigran Technologies and Retinalyze.

He has a Bachelor of Science in Business Administration and Economics from the University of Lund, Sweden.

Jónas Einarsson, Chairman of Targovax, comments: "We are delighted to welcome Gunnar Gårdemyr to Targovax. Our ability to attract an experienced industry executive with Gunnar's track record and knowledge reflects Targovax` potential. His leadership will accelerate the company's further development.

"We are also very grateful to Hanne Mette D. Kristensen for her contribution by leading Targovax from establishment to a phase II company." 

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.